A Samsung Bioepis study published in BMJ Open Ophthalmology demonstrated that SB15, its biosimilar to Regeneron’s Eylea® (aflibercept), had comparable efficacy, safety, pharmacokinetics and immunogenicity to Eylea® up to week 56 in patients with neovascular age- related macular degeneration (nAMD). The study also showed that switching from Eylea® to SB15 maintained comparable clinical efficacy and safety. The authors claim that the results support biosimilarity between SB15 and Eylea®.
Samsung Bioepis announced the phase III switching study results for SB15 on 7 October 2023.